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Abstract
Background: The host range of human immunodeficiency virus (HIV) is quite
narrow. Therefore, analyzing HIV-1 pathogenesis in vivo has been limited owing to
lack of appropriate animal model systems. To overcome this, chimeric simian and
human immunodeficiency viruses (SHIVs) that encode HIV-1 Env and are infectious
to macaques have been developed and used to investigate the pathogenicity of
HIV-1 in vivo. So far, we have many SHIV strains that show different pathogenesis in
macaque experiments. However, dynamic aspects of SHIV infection have not been
well understood. To fully understand the dynamic properties of SHIVs, we focused
on two representative strains—the highly pathogenic SHIV, SHIV-KS661, and the less
pathogenic SHIV, SHIV-#64—and measured the time-course of experimental data in
cell culture.
Methods: We infected HSC-F with SHIV-KS661 and -#64 and measured the
concentration of Nef-negative (target) and Nef-positive (infected) HSC-F cells, the
total viral load, and the infectious viral load daily for 9 days. The experiments were
repeated at two different multiplicities of infection, and a previously developed
mathematical model incorporating the infectious and non-infectious viruses was
fitted to the full dataset of each strain simultaneously to characterize the infection
dynamics of these two strains.
Results and conclusions: We quantified virological indices including virus burst sizes
and basic reproduction number of both SHIV-KS661 and -#64. Comparing the burst size
of total and infectious viruses (viral RNA copies and TCID50, respectively), we found that
there was a statistically significant difference between the infectious virus burst size of
SHIV-KS661 and -#64, while there was no significant difference between the total virus
burst size. Furthermore, our analyses showed that the fraction of infectious virus among
the produced SHIV-KS661 viruses, which is defined as the infectious viral load (TCID50/
ml) divided by the total viral load (RNA copies/ml), is more than 10-fold higher than
that of SHIV-#64 during overall infection (i.e., for 9 days). Taken together, we conclude
that the highly pathogenic SHIV produces infectious virions more effectively than the
less pathogenic SHIV in cell culture.
Keywords: Population dynamics model, Parameter estimation, Virus dynamics, Simian/
human immunodeficiency virus
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Background
Human immunodeficiency virus (HIV) is able to infect only humans and chimpanzees.
This narrow host range makes it difficult for us to establish an appropriate “animal
experimental system” for HIV research in order to more fully understand the pathogen-
esis of HIV infection in vivo. To overcome these difficulties, chimeric simian and
human immunodeficiency viruses (SHIVs) that encode HIV-1 Env and are infectious to
macaques have been developed [1–3]. For example, a highly pathogenic SHIV strain,
SHIV-KS661, which has the env gene of HIV-1 89.6 and predominantly uses CXCR4 as
the secondary receptor for infection, causes an infection that systemically depletes the
CD4+ T-cells of rhesus macaques within 4 weeks following infection [4, 5]. On the
other hand, a less pathogenic strain, SHIV-#64, which also predominantly uses CXCR4
as the secondary receptor, does not cause severe symptoms in rhesus macaques [6]. In
particular, SHIV-#64 infected macaques do not show systemic depletion of CD4+
T-cells after infection because viral replication is suppressed by the host immune
response [6]. Unlike SHIV-KS661 infection [3, 7], the reduced CD4+ T-cell deple-
tion observed in SHIV-#64 infection might lead to better T-cell dependent help for
both antibody and CD8+ T-cell responses to the virus [6, 8]. So far, we have many
SHIV strains that show different pathogenesis in macaque experiments [1–7, 9, 10].
In our previous study [11], we quantified only SHIV-KS661 infection in vitro.
However, dynamic aspects of other SHIV strains are not well understood. Quantify-
ing and comparing viral kinetics will provide us with novel insights into the patho-
genesis of SHIV strains (and HIV-1) [11–14]. To extend our understanding of the
dynamic properties of SHIVs in this study, we focused on two representative
strains: SHIV-KS661 and SHIV-#64, and measured the detailed time-course of
experimental data in HSC-F cell culture. Using our previously developed method
combining in vitro experiments and a mathematical model published in our previ-
ous paper [11], we characterized SHIV-KS661 and -#64, and showed a difference
between strains based on virological indices including the virus burst sizes and
basic reproduction number. Our main finding was that the fraction of infectious
virus among the SHIV-KS661 virus progeny is more than 10-fold higher than that
of SHIV-#64 during the overall infection in our cell culture. This is a valuable
complement to the well-developed in vivo model and can be used to significantly
improve our knowledge of SHIV and HIV pathogenesis in vivo.
Methods
Cell culture experiment
Our experimental procedures have been previously published [13] but are repeated
here for completeness. The virus solution of SHIV-KS661 [5] (or SHIV-#64 [6]) was
prepared in a CD4+ human T lymphoid cell line, M8166 (a subclone of C8166) [15],
and was stored in liquid nitrogen until use. The HSC-F cell line [16] was cultured in a
culture medium (RPMI-1640 supplemented with 10% fetal calf serum) at 37 °C and 5%
CO2 in humidified conditions. Each experiment was performed using two wells of a 24-
well plate with a total suspension volume of 2 ml (1 ml per well) and an initial cell con-
centration of T0 = 6.46 × 10
6 cells/ml in each well. Because the initial cell concentration
was close to the carrying capacity of a 24-well plate and HSC-F cells replicate slowly, in
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the absence of SHIV-KS661 (or SHIV-#64) infection the population of target cells
changed very little during the timescale of our experiment (data not shown). We there-
fore neglected the effects of potential regeneration of HSC-F cells in our analysis and in
constructing the mathematical model. For virus infection, cultures of HSC-F cells were
inoculated 24 h prior to the first infection sampling (t = −24 h) at two different multi-
plicities of infection (MOIs) of 2.0 × 10−4 or 2.0 × 10−5 50% tissue culture infectious
dose (TCID50) per cell of SHIV-KS661 (or SHIV-#64), and were incubated at 37 °C.
Four hours after inoculation (t = −20 h), the cells were washed to remove the remaining
viruses and were replaced into fresh culture medium. The culture supernatant was har-
vested daily for 10 days (t = 0,1,…,9d), and was replaced with fresh medium. On a daily
basis, 5.5% of the cells in the culture were harvested to measure the concentration of tar-
get and infected cells. Cells were counted by staining with an anti-SIV Nef monoclonal
antibody (04-001, Santa Cruz Biotechnology, Santa Cruz, CA) labeled with Zenon Alexa
Fluor 488 (Invitrogen, Carlsbad, CA), as previously described [11, 12]. Each harvested
supernatant, including 85.4% of the culture virus was stored at -80 °C, and the amount of
viral RNA was quantified by RT-PCR, as previously described [11, 12, 17]. The infectious
viral load was measured by TCID50 assay in HFC-S cell cultures using 96-well flat bottom
plates at cell concentrations of 1.0 × 106 cells/ml. The titer of the virus was determined as
described by Reed and Muench [18].
Mathematical model
We employed the following mathematical model considering the infectious and non-
infectious viruses, which was developed in our previous paper [11]:
T′ tð Þ ¼ −βT tð ÞVI tð Þ−dT tð Þ; ð1Þ
I′ tð Þ ¼ βT tð ÞV I tð Þ−δI tð Þ; ð2Þ
VI′ tð Þ ¼ f pRNAI tð Þ−c50V I tð Þ−cRNAV I tð Þ; ð3Þ
VNI′ tð Þ ¼ 1−fð ÞpRNAI tð Þ þ c50V I tð Þ−cRNAVNI tð Þ; ð4Þ
where T(t) and I(t) are the concentration of target (susceptible: Nef-negative HSC-F
cells) and infected (virus-producing: Nef-positive HSC-F cells) cells per ml of medium,
respectively, and VI (t) and VNI (t) are the concentration of RNA copies of infectious
and non-infectious virus per ml of medium, respectively. Parameters d, δ, cRNA and
β represent the death rate of target cells, the death rate of infected cells, the deg-
radation rate of viral RNA and the rate constant for infection of target cells by
virus, respectively. We assumed that each infected cell releases pRNA virus particles
per day (i.e., pRNA is the viral production rate of an infected cell), of which a frac-
tion f are infectious and 1 - f are non-infectious. Infectious virions lose infectivity
at rate c50, becoming non-infectious. A detailed explanation of Eqs. (1,2,3 and 4)
can be found in our previous paper [11].
Mathematical model for data analysis
In the experiments discussed above, the viral load was measured either as the total
count of extracellular virions, expressed as RNA copies/ml (two RNA copies equals
one virion) and measured via quantitative PCR, or as a relative concentration of extra-
cellular infectious virions, expressed as TCID50/ml (proportional to the concentration
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of infectious virions) and measured via virus titration in cell cultures. To analyze our
cell culture experimental datasets, the time-course of the concentration of Nef-negative
and Nef-positive HSC-F cells and the viral loads consisting of RNA copies/ml and
TCID50/ml, for SHIV-KS661 and -#64, we transformed Eqs. (1,2,3 and 4) into the fol-
lowing scaled model [11]:
T′ tð Þ ¼ −β50T tð ÞV 50 tð Þ−dT tð Þ−μT tð Þ; ð5Þ
I′ tð Þ ¼ β50T tð ÞV 50 tð Þ−δI tð Þ−μI tð Þ; ð6Þ
VRNA′ tð Þ ¼ pRNAI tð Þ−cRNAVRNA tð Þ−cVRNA tð Þ; ð7Þ
V 50′ tð Þ ¼ p50I tð Þ−c50V 50 tð Þ−cRNAV 50 tð Þ−cV 50 tð Þ; ð8Þ
where VRNA(t) =VI(t) + VNI(t) is the total concentration of viral RNA copies, V50(t)
= αVI(t) is the infectious viral load expressed in TCID50/ml, and α is the conversion
factor from infectious viral RNA copies to TCID50. Parameters β50 = β/α and p50
= αfpRNA are the converted infection rate constant and production rate of infectious
virus, respectively. For each of the daily measurements of the cells and virus concentra-
tion, the concentration of Nef-negative and Nef-positive HSC-F cells must be reduced
in our model by 5.5% and the viral loads (RNA copies and TCID50) by 85.4% to account
for the experimental harvesting of cells and virus. These losses were modeled in
Eqs. (5,6,7 and 8) by approximating the sampling of cells and virus as a continuous
exponential decay, yielding a rate of μ = 0.057 per day for cell harvest (i.e., log(1 − 0.055))
and c = 1.93 per day for virus harvest (i.e., log(1 − 0.854)). The rates at which SHIV-KS661
and -#64 virions lose infectivity, c50 = 0.869 and 0.992, per day and the rate at which their
viral RNA degrades, cRNA = 0.091 and 0.160, per day were each estimated directly
in separate experiments [13]. These parameter values are summarized in Table 1.
Parameter estimation
The Bayesian inference model adopted in this paper assumes measurement error to follow
normal distribution with mean zero and unknown variance (error variance). A distribu-
tion of error variance is also inferred with the Gamma distribution as its prior distribu-
tion. Posterior predictive parameter distributions as an output of Markov chain Monte
Carlo (MCMC) computation represents parameter variability. In relating our daily experi-
mental measurements at time t = 0,1,…,9 day to our mathematical models, we define t = 0
as the time of our first experimental measurements, i.e. when T(0), I(0), VRNA(0), and
V50(0) are measured. As such, by time t = 0, some cells (T) have become infected (I), and
while the inoculum virus has been washed, some new virus (V50) will have been produced
by the newly infected cells. The remaining five free model parameters (β50, d, δ, pRNA, p50)
along with eight initial (t = 0) values for the variables (four at each of the two MOI values)
were determined. Distributions of the model parameters and the initial values were in-
ferred directly by MCMC computations. On the other hand, distributions of the basic
reproduction numbers and the other quantities were calculated from the inferred param-
eter sets (see Figs. 2 and 3a,b for graphical representation). A set of computations for Eqs.
(5,6,7 and 8) with estimated parameter sets gives a distribution of outputs (virus load and
cell density) as model predictions. To investigate the variation of model predictions, global
sensitivity analyses were performed. The range of possible variation is drawn in Figs. 1
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and 3c as 95% credible intervals. Technical details of MCMC computations and repeated
bootstrap t-test are summarized in Additional file 1.
Results and Discussion
Data fitting to quantify SHIV-KS661 and -#64 infection in HSC-F cells
Correctly estimated parameter sets with possible variation are required to reproduce
model predictions for quantification of SHIV dynamics [19–21]. However, point esti-
mation of the model parameter set by a conventional ordinary least square method
does not capture possible variations of kinetic parameters and model predictions (see
Additional file 2: Figure S1, Additional file 3: Table S1, and Additional file 4: Table S2).
To assess the variability of kinetic parameters and model predictions, we performed
Bayesian estimation for the whole dataset using MCMC sampling (see Methods and
Additional file 1), and simultaneously fitted Eqs. (5,6,7 and 8) to the concentration of
Nef-negative and Nef-positive HSC-F cells and the viral loads consisting of RNA cop-
ies/ml and TCID50/ml with different MOI values, for SHIV-KS661 and -#64, respect-
ively, as described in [19–21]. We used the parameters in Additional file 3: Table S1
and Additional file 4: Table S2 as the initial estimate of MCMC sampling.
The remaining five free model parameters (β50, d, δ, pRNA, p50) along with eight initial
values for the variables were determined by fitting the model to the data. Experimental
measurements, which were below the detection limit, were excluded in the fitting. The
estimated parameters of the model and derived quantities are given in Table 1, and the
estimated initial values are summarized in Table 2. The typical behavior of the model
using these best-fit parameter estimates is shown together with the data in Fig. 1 for
SHIV-KS661 and -#64, which reveals that Eqs. (5,6,7 and 8) describe these in vitro data
Fig. 1 Dynamics of SHIV-KS661 and -#64 infection in HSC-F cells. HSC-F cells were inoculated with SHIV-
KS661 or -#64 at two different multiplicities of infection (i.e., 2.0 × 10−4 or 2.0 × 10−5 TCID50 per cell) in cell
cultures. Panels show the time-course of experimental data (log scale) for the concentration of Nef-negative
and Nef-positive HSC-F cells and the viral loads consisting of RNA copies/ml and TCID50/ml for SHIV-KS661
and -#64, respectively. The shadow regions correspond to 95% posterior predictive intervals, the solid curves
give the best-fit solution (mean) for Eqs. (5,6,7 and 8) to the time-course dataset. All data for each strain
were fitted simultaneously
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very well. The shadowed regions correspond to 95% posterior predictive intervals, the
solid lines give the best-fit solution (mean) for Eqs. (5,6,7 and 8), and the dots show the
experimental datasets.
Malthusian parameter and basic reproduction number for SHIV-KS661 and -#64 in
HSC-F cells
The fitness (or speed) of a SHIV strain in cell culture is described by the Malthusian
coefficient, M, defined for Eqs. (5,6,7 and 8) [20–22]. Here, the Malthusian coefficient is
M ¼
− δ þ μþ cRNA þ c50 þ cð Þ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




Using estimated parameter distributions, we calculated the distribution of M for
SHIV-KS661 and -#64 in Fig. 2a (see Methods). The mean values of M for SHIV-KS661
and -#64 are significantly different (Fig. 2a; p = 6 × 10−6 by repeated bootstrap t-test, see
Additional file 1) at 3.08 (95% confidence interval (CI): 2.82–3.52) and 2.59 (95% CI:
2.37–2.80), respectively (Table 1). This difference in the value of M between SHIV-
KS661 and -#64 might explain the earlier and more rapid viral load expansion (i.e., peak









































Fig. 2 Distribution of Malthusian coefficients and basic reproduction numbers for SHIV-KS661 and -#64 in
HSC-F cells. The distributions of the Malthusian coefficients, M, and the basic reproduction numbers, R0
*,
that were calculated from the estimated parameter distributions are shown in (a) and (b), respectively, for
SHIV-KS661 (red) and -#64 (blue) strains. These indices of M and R0
* for SHIV-KS661 are significantly different
from those for SHIV-#64, as assessed by the repeated bootstrap t-test
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within a few weeks of SHIV-KS661 infection [3–7], implying a strong relationship
between SHIV replication ability and its disease severity.
The other important quantity characterizing virus dynamics is the basic reproduction
number, R0
* , which is the average number of newly infected cells produced from any
one infected cell, under conditions where most of the target cells are uninfected
[11, 12, 20–22]. In Eqs. (5,6,7 and 8), the basic reproduction number is defined as
R0 ¼ β50p50T 0ð Þ= δ þ μð Þ cRNA þ c50 þ cð Þf g:
Similarly, we calculated the distributions of R0
* for SHIV-KS661 and -#64 (Fig. 2b).
The mean value of R0
* for SHIV-KS661 is 6.25 (95% CI: 5.29–7.51), which is signifi-
cantly higher (Fig. 2b; p = 4.2 × 10− 5 by the repeated bootstrap t-test) than that of
SHIV-#64 (4.84; 95% CI: 4.13–5.62) (Table 1). Again, this difference in the value of R0
*
between SHIV-KS661 and -#64 implies that the highly pathogenic SHIV strain more
efficiently causes systemic CD4+ T-cell depletion. In Additional file 5: Figure S2, we
calculated the distribution of the basic reproduction number without the effects of
removal, R0 = β50p50T(0)/δ(cRNA + c50), defined in our previous paper [14] and observed
the same trend.
Viral burst size for SHIV-KS661 and -#64 in HSC-F cells
Interestingly, we found the viral fitness (or speed), M, and the infection potential, R0
* , of
SHIV-KS661 were significantly higher than those of SHIV-#64 in HSC-F cells (Fig. 2).
Hereafter, to quantitatively explain a possible mechanism that there are significant
differences between SHIV strains, we investigated and compared the total and infec-
tious virus burst sizes (i.e., pRNA/δ and p50/δ, respectively) [11]. In Fig. 3a and b, we
calculated the distributions of burst sizes for SHIV-KS661 and -#64 using all accepted
MCMC estimated parameter values. Surprisingly, we found that there was a statistically
significant difference in the infectious burst size, measured in TCID50, between SHIV-
KS661 and -#64 (Fig. 3b; p = 2.5 × 10− 5 by the repeated bootstrap t-test), while there
was no significant difference in the total burst size, measured in viral RNA copies
(Fig. 3a; p = 0.34 by the repeated bootstrap t-test). This implies that the highly patho-
genic SHIV produces more infectious virions compared with the less pathogenic strain.
In addition, we compared experimental measurement of the infectious viral load as a
proportion of the total viral load (i.e., the fraction of the infectious virus among the
produced viruses), with the time evolution of the proportion calculated by our math-
ematical model (i.e.,V50(t)/VRNA(t)) in Fig. 3c. Despite MOI values and time post infec-
tion, we confirmed that the experimental proportions were shown to be steady state
values, and the model predictions converged with those values for both SHIV strains.
Of great interest was the more than 10-fold difference in the ratios between SHIV-
KS661 and -#64 during the overall infection. This strongly supports our above hypoth-
esis that the highly pathogenic SHIV effectively produces infectious virions, which leads
to earlier and more rapid viral load expansion and the systemic depletion of the CD4+
T-cells in SHIV-KS661-infected rhesus macaques.
Conclusion
We inoculated HSC-F cells with SHIV-KS661 or -#64 at two different MOIs (i.e., 2.0 ×
10−4 or 2.0 × 10−5 TCID50 per cell) and measured in detail the time-course of the
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experimental data (i.e., the concentration of Nef-negative and Nef-positive HSC-F cells
and the viral loads consisting of RNA copies/ml and TCID50/ml). Using our previously
developed method combining in vitro experiments and a mathematical model in our
previous paper [11], we quantified and compared the basic reproduction numbers and




Fig. 3 Dynamics of infectious virus for SHIV-KS661 and -#64 in HSC-F cells. The distributions of the total viral
burst size (RNA copies), pRNA/δ, and the infectious burst size (TCID50), p50/δ, that were calculated from the
estimated parameter distributions are shown in (a) and (b), respectively, for SHIV-KS661 (red) and -#64 (blue)
strains. The time-course of the infectious viral load as a proportion of the total viral load are calculated in
(c). The shadow regions correspond to 95% posterior predictive intervals, the solid and dashed curves give
the best-fit solution (mean) for V50(t)/ VRNA(t) to the time-course datasets. The pink (solid curve and round
points) and red (dashed curve and triangular points) colors correspond to 2.0 × 10−4 and 2.0 × 10−5 MOI of
SHIV-KS661, while the light blue (solid curve and round points) and blue (dashed curve and triangular points)
colors correspond to 2.0 × 10−4 and 2.0 × 10−5 MOI of SHIV-#64, respectively
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we concluded that SHIV-KS661 effectively produces infectious virions compared with
SHIV-#64 in the HSC-F cell culture. SHIV-KS661 contains mutations in the pol and
env genes, which are considered to lead SHIV-KS661 to produce more virus and have
higher infectivity than SHIV-#64 (data not shown), which is consistent with our conclu-
sion. Although we used the Malthusian parameter, M, and the basic reproduction num-
ber, R0
* to compare the differences in viral characteristics here, we need to consider
evasion of the acquired immune response in infected rhesus macaques to further
understand the differing pathogenesis displayed by these viruses, such as systemic CD4
+ T-cell depletion in SHIV-KS661 infections. Since we cannot observe the effect of the
immune response in our cell culture experiments, it will be necessary to analyze the in
vivo data from SHIV infected macaques in future work.
Additional files
Additional file 1: Technical details of MCMC computations. (PDF 49 kb)
Additional file 2: Figure S1. Dynamics of SHIV-KS661 and -#64 infection in HSC-F cells using nonlinear least-
squares regression. We simultaneously fit Eqs. (5,6,7 and 8) to the concentrations of Nef-negative and Nef-positive
HSC-F cells and the viral loads consisting of the RNA copies/ml and TCID50/ml for both MOIs of SHIV-KS661 and
-#64, respectively, in A and B using nonlinear least-squares regression that minimizes the sum of squared residuals
(SSR). Experimental measurements below the detection limit were excluded when 2 computing the SSR. The solid
curves give the best-fit solution for Eqs.(5,6,7 and 8) and the dots are corresponding to the time-course dataset
(log scale): blue, red, green, and yellow represent Nef-negative and Nef-positive HSC-F cells and the viral loads
consisting of the RNA copies/ml and TCID50/ml, respectively. The estimated parameters of the model and derived
quantities are given in Additional file 3: Table S1, and the estimated initial values are summarized in Additional file
4: Table S2. (PDF 146 kb)
Additional file 3 Table S1. Parameter values for the in vitro experiment by the nonlinear least squared methods.
(PDF 57 kb)
Additional file 4: Table S2. Fitted initial (t = 0) values for the in vitro experiment by the nonlinear least squared
methods. (PDF 64 kb)
Additional file 5: Figure S2 Distribution of basic reproduction numbers without removal for SHIV-KS661 and
-#64 in HSC-F cells. The distributions of the basic reproduction numbers without the effect of removal, R0=β50p50T
(0)/δ(cRNA+c50), that were calculated from the estimated parameter distributions are shown for SHIV-KS661 (red)
and -#64 (blue) strains. The basic reproduction number for SHIV-KS661 is significantly different from that for SHIV-
#64, as assessed by the repeated bootstrap t-test. (PDF 117 kb)
Abbreviations
HIV: Human immunodeficiency virus; MCMC: Markov chain Monte Carlo; MOI: Multiplicity of infection; SHIV: Simian and




This work was supported in part by the JSPS Research Fellowship for Young Scientists Grant Number 16 J03672 (to Y.K.);
the Japan Science and Technology Agency (JST) PRESTO program (to S.N. and S.I.); JST RISTEX program (to S.I.); JST CREST
program (to S.I.); the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers 26400388 (to S.M.);
16H04682 (to T.M.); 15KT0147, 15H05707, and 16 K05265 (to S.N.); 15KT0107, 26287025, 16KT0111, 16H04845, and
16 K13777 (to S.I.); the Japan Agency for Medical Research and Development, AMED, Grant Numbers 16fk0410102h0001,
16fk0410201h0102, 16fk0410208h0002, and 15fk0410014h0001 (to T.M.); 16fk0108316h0003 (to S.I.); Mitsui Life Social Welfare
Foundation (to. S.I.); The Shin-Nihon of Advanced Medical Research (to S.I.); GSK Japan Research Grant 2016 (to S.I.).
Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author
on reasonable request.
Authors’ contributions
Conceived and designed the study: TM SI. Analyzed the data: SI YK SM SN SI. Wrote the paper: TM SN SI. Contributed
reagents/materials/analysis tools: TM. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Iwanami et al. Theoretical Biology and Medical Modelling  (2017) 14:9 Page 11 of 13
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1Department of Biology, Kyushu University, Nishi-ku, Fukuoka, Japan. 2Department of Mathematical and Systems
Engineering, Shizuoka University, Hamamatsu, Shizuoka, Japan. 3Institute for Frontier Life and Medical Sciences, Kyoto
University, Kyoto, Japan. 4PRESTO, JST, Kawaguchi, Saitama, Japan. 5Institute of Industrial Science, The University of
Tokyo, Meguro-ku, Tokyo, Japan. 6CREST, JST, Kawaguchi, Saitama, Japan.
Received: 13 January 2017 Accepted: 18 April 2017
References
1. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected
with CCR5 or CXCR4 utilizing SHIVs. Science (New York, NY). 1999;284(5415):816–9. Epub 1999/04/30.
2. Matsuda K, Inaba K, Fukazawa Y, Matsuyama M, Ibuki K, Horiike M, et al. In vivo analysis of a new R5 tropic SHIV
generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. Virology. 2010;399(1):134–43.
doi:10.1016/j.virol.2010.01.008. Epub 2010/01/28.
3. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, et al. Highly pathogenic SHIVs and SIVs
target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad
Sci U S A. 2004;101(33):12324–9. Epub 2004/08/07. doi: 10.1073/pnas.0404620101. PubMed PMID: 15297611; PubMed
Central PMCID: PMCPMC514404.
4. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, et al. A chimeric simian/human immunodeficiency
virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease
after in vivo passage in rhesus monkeys. J Virol. 1996;70(10):6922–8. Epub 1996/10/01. PubMed PMID: 8794335;
PubMed Central PMCID: PMCPMC190741.
5. Shinohara K, Sakai K, Ando S, Ami Y, Yoshino N, Takahashi E, et al. A highly pathogenic simian/human
immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol. 1999;80(Pt 5):1231–40.
doi:10.1099/0022-1317-80-5-1231. Epub 1999/06/04.
6. Kozyrev IL, Ibuki K, Shimada T, Kuwata T, Takemura T, Hayami M, et al. Characterization of less pathogenic infectious
molecular clones derived from acute-pathogenic SHIV-89.6p stock virus. Virology. 2001;282(1):6–13. doi:10.1006/viro.
2000.0839. Epub 2001/03/22.
7. Nishimura Y, Brown CR, Mattapallil JJ, Igarashi T, Buckler-White A, Lafont BA, et al. Resting naive CD4+ T cells are
massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl
Acad Sci U S A. 2005;102(22):8000–5. Epub 2005/05/25. doi: 10.1073/pnas.0503233102. PubMed PMID: 15911767;
PubMed Central PMCID: PMCPMC1142395.
8. Davenport MP, Ribeiro RM, Zhang L, Wilson DP, Perelson AS. Understanding the mechanisms and limitations of
immune control of HIV. Immunol Rev. 2007;216:164–75. doi:10.1111/j.1600-065X.2006.00485.x. Epub 2007/03/21.
9. Otsuki H, Yoneda M, Igarashi T, Miura T. Generation of a monkey-tropic human immunodeficiency virus type 1
carrying env from a CCR5-tropic subtype C clinical isolate. Virology. 2014;460-461:1–10. Epub 2014/07/11.
doi: 10.1016/j.virol.2014.04.037.
10. Ishida Y, Yoneda M, Otsuki H, Watanabe Y, Kato F, Matsuura K, et al. Generation of a neutralization-resistant CCR5
tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6. J Gen Virol.
2016;97(5):1249–60. doi:10.1099/jgv.0.000421. Epub 2016/02/07.
11. Iwami S, Holder BP, Beauchemin CA, Morita S, Tada T, Sato K, et al. Quantification system for the viral dynamics of
a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical
model. Retrovirology. 2012;9:18. doi:10.1186/1742-4690-9-18. Epub 2012/03/01. PubMed PMID: 22364292; PubMed
Central PMCID: PMCPMC3305505.
12. Iwami S, Sato K, De Boer RJ, Aihara K, Miura T, Koyanagi Y. Identifying viral parameters from in vitro cell cultures.
Front Microbiol. 2012;3:319. doi:10.3389/fmicb.2012.00319. Epub 2012/09/13. PubMed PMID: 22969758; PubMed
Central PMCID: PMCPMC3432869.
13. Kakizoe Y, Morita S, Nakaoka S, Takeuchi Y, Sato K, Miura T, et al. A conservation law for virus infection kinetics in
vitro. J Theor Biol. 2015;376:39–47. doi:10.1016/j.jtbi.2015.03.034. Epub 2015/04/18.
14. Kakizoe Y, Nakaoka S, Beauchemin CA, Morita S, Mori H, Igarashi T, et al. A method to determine the duration of
the eclipse phase for in vitro infection with a highly pathogenic SHIV strain. Sci Rep. 2015;5:10371. doi:10.1038/
srep10371. Epub 2015/05/23. PubMed PMID: 25996439; PubMed Central PMCID: PMCPMC4440524.
15. Clapham PR, Weiss RA, Dalgleish AG, Exley M, Whitby D, Hogg N. Human immunodeficiency virus infection of
monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology.
1987;158(1):44–51. Epub 1987/05/01.
16. Akari H, Mori K, Terao K, Otani I, Fukasawa M, Mukai R, et al. In vitro immortalization of Old World monkey
T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses.
Virology. 1996;218(2):382–8. doi:10.1006/viro.1996.0207. Epub 1996/04/15.
Iwanami et al. Theoretical Biology and Medical Modelling  (2017) 14:9 Page 12 of 13
17. Motohara M, Ibuki K, Miyake A, Fukazawa Y, Inaba K, Suzuki H, et al. Impaired T-cell differentiation in the thymus at the
early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less
pathogenic SHIV infection. Microbes Infect. 2006;8(6):1539–49. doi:10.1016/j.micinf.2006.01.011. Epub 2006/05/17.
18. Reed L, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493–7.
19. Ikeda H, Nakaoka S, de Boer RJ, Morita S, Misawa N, Koyanagi Y, et al. Quantifying the effect of Vpu on the promotion
of HIV-1 replication in the humanized mouse model. Retrovirology. 2016;13:23. doi:10.1186/s12977-016-0252-2.
Epub 2016/04/19. PubMed PMID: 27086687; PubMed Central PMCID: PMCPMC4834825.
20. Iwami S, Takeuchi JS, Nakaoka S, Mammano F, Clavel F, Inaba H, et al. Cell-to-cell infection by HIV contributes over
half of virus infection. eLife. 2015;4. Epub 2015/10/07. doi: 10.7554/eLife.08150. PubMed PMID: 26441404; PubMed
Central PMCID: PMCPMC4592948.
21. Martyushev A, Nakaoka S, Sato K, Noda T, Iwami S. Modelling Ebola virus dynamics: Implications for therapy. Antivir Res.
2016;135:62–73. doi:10.1016/j.antiviral.2016.10.004. Epub 2016/10/28.
22. Nowak M, May RM. Virus dynamics: mathematical principles of immunology and virology: mathematical principles
of immunology and virology. UK: Oxford University Press; 2000.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Iwanami et al. Theoretical Biology and Medical Modelling  (2017) 14:9 Page 13 of 13
